Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other 1

Conditions

Multiple Myeloma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Dyspnea 1Cardiotoxicity 1Burkitt Lymphoma 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Echocardiography × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡